Specificity
Focus on Alzheimer's-related markers rather than a broad molecular panel.
AD-Detect is NeuroAge's Alzheimer's-focused blood test, using the Quest Diagnostics workflow to measure Aβ42/40 and p-tau217 and support personalized recommendations based on Alzheimer's-related biomarkers.
This page is specifically about Alzheimer's-related pathology biomarkers rather than a broader RNA-style biomarker panel, with personalized recommendations guided by those findings.
AD-Detect is designed for people who want an Alzheimer's-focused biomarker signal rather than a broader biological aging panel.
NeuroAge's current science materials describe AD-Detect through a Quest Diagnostics blood-draw workflow. The product focuses on blood-based Alzheimer's biomarkers, including Aβ42/40 and p-tau217.
That makes AD-Detect distinct from the broader Blood Biomarkers Test. This page is intentionally centered on Alzheimer's-related pathology rather than upstream biology in general, so recommendations can be interpreted in a more targeted context.
Focus on Alzheimer's-related markers rather than a broad molecular panel.
Use the Quest Diagnostics workflow for a standard blood draw experience.
Add AD-Detect to genetics, MRI, NeuroGames, or coaching when you want a fuller prevention picture.
AD-Detect is a strong fit when you want a more targeted blood test rather than a broader biomarker panel.
Choose this product when your main concern is Alzheimer's-related pathology rather than general biological aging.
Use a blood draw when you want a targeted signal without starting with MRI.
Combine AD-Detect with genetics, cognition, or imaging for broader context if desired.
This page is intentionally distinct from the broader Blood Biomarkers Test.
NeuroAge's current science materials describe AD-Detect as a Quest Diagnostics blood-draw workflow centered on Alzheimer's biomarkers. The highlighted markers include Aβ42/40 and p-tau217, which are framed as the product's core pathology-focused signals.
That narrower focus is the point. AD-Detect is for people who want an Alzheimer's-specific blood-based layer, while the broader Blood Biomarkers Test is designed around upstream biology such as neuroinflammation, mitochondrial function, and cellular stress.
The dashboard section helps place AD-Detect results alongside your broader NeuroAge context when needed.
Review Alzheimer's-focused blood findings in a clearer visual format.
Keep pathology-oriented results accessible for follow-up conversations and personalized recommendations.
Pair AD-Detect with other product results when you want broader context.

What NeuroAge customers are saying across imaging, testing, and coaching.
NeuroAge's current science materials emphasize Aβ42/40 and p-tau217 as the core Alzheimer's-focused biomarkers for AD-Detect.
After purchase, you visit a Quest Diagnostics location for a standard blood draw. The product is built around that Quest Diagnostics workflow.
AD-Detect is centered on Alzheimer's-related pathology markers. The Blood Biomarkers Test is positioned around broader brain-aging biology instead.
No. It is an Alzheimer's-focused biomarker product that can inform next-step discussions, but it does not replace physician-led diagnosis.
Use the Quest Diagnostics workflow to access Aβ42/40 and p-tau217 in a more targeted product with personalized recommendations for next steps.